尿毒灵对糖尿病肾病肾功能不全的临床与实验研究
|
摘要
1.目的意义
本研究主要是对尿毒灵的临床疗效进行观察,对于严格按照诊断标准、纳入标准的情况下选取患者用药,并观察其证候积分、生化等指标变化;同时对于尿毒灵的作用机制,以TGF/smad转导通路为研究指标,进行探索性实验研究;至在寻找DN新的治疗药物,对名老专家经验方进行临床疗效及作用机制同时研究,为开发新药做好准备。
2.方法
住院和门诊的糖尿病人中筛选出符合DN诊断标准的病人,符合诊断标准,血肌酐178≤(Cr)≤442ummol/l,排除其它原因引起的肾功能不全,观察30例患者,观察三个月,观察用药前后患者症候积分、生化、血脂、肝功、血常规变化情况,及最后疗效。
SPF级雄性Wister大鼠48只,体重180-220g,适应性喂养一周。按体重随机分为正常对照组12只,剩余36只用于造模。造模方法选为STZ(链脲佐菌素)+腺嘌呤灌胃:将STZ用缓冲液(2.1g柠檬酸溶于100ml双蒸水中配成A液,2.44g柠檬酸钠溶于100ml双蒸水中为B液,A、B液混合即为缓冲液)配置,36只大鼠禁食12小时,STZ以剂量为60mg/kg体重,一次性腹腔注射,三天后测随机血糖,血糖大于16.1mmol/l的大鼠,造模成功,为减少死亡率血糖大于25mmol/l的大鼠皮下注射普通胰岛素1-2iu,血糖不足16.1mmol/l的大鼠,补注射STZ 20mg/kg;全部成模后,予2%腺嘌呤,300mg/kg灌胃,每7天取一次眶静脉血直至成模。造模过程中死亡5只,成模后剩余31只大鼠,按随机表随机分组,分为模型组、尿毒灵组、尿毒清组;模型组灌胃给予2-4ml生理盐水,尿毒灵组予尿毒灵组0.432g/kg,尿毒清组予尿毒清0.27g/kg;给药两个月后,眶静脉丛取血测生化指标,取部分肾脏做免疫组化,部分肾脏做RT-PCR。
3.结果
实验研究部分:给药组与模型组相比较,尿毒灵组血肌酐、尿素氮下降有统计学意义;尿毒灵组与模型组相比胆固醇、甘油三酯、低密度脂蛋白胆固醇差异不显著,无统计学意义;TGF-β1、Smad3、Smad4、PAI-1在模型组的表达均较空白组有明显增加,有统计学意义,P＜0.05,尿毒灵组上述蛋白的表达均较模型组有明显下降;RT-PCR检测大鼠肾组织TGF-β1mRNA、Smad3 mRNA、Smad4 mRNA,荧光定量PCR检测各指标在肾组织的表达,模型组与空白组比较有显著性差异,P＜0.05,尿毒灵组、尿毒清组与模型组相比差异显著,P＜0.05,给药后有统计学意义。
临床观察部分:
尿毒灵疗效:显效5例,占16.67%;有效21例,占70%;无效4例,占13.33%;总有效率86.67%。用药前后对照,患者症候积分下降有统计学意义(P＜0.01)。
用药前后对照,患者尿素氮,血肌酐下降有统计学意义(P＜0.05);患者CHOL、TG和LDL-L的水平下降有统计学意义(P＜0.05);安全性指标肝功能用药前后比较无统计学意义,血常规白细胞、红细胞无明显变化,血红蛋白有所上升。
4.结论
经实验研究得出如下结论:尿毒灵有很好的清除血中肌酐,尿素氮等毒素的作用。,尿毒灵具有很好的降低转化生长因子(TGF-β)、纤溶酶原激活物抑制物(PAI-1)在肾脏小球、间质、小管的表达,抑制TGF-β1、smad3、smad4 mRNA合成的作用。所以可以得出结论尿毒灵可以抑制TGF-β/Smad转导通路。尿毒灵可能是通过抑制TGF-β/Smad转导通路,而达到抑制肾小球、肾间质、肾小管纤维化,从而起到肾保护作用。
通过对尿毒灵的临床观察,对观察指标及安全性指标的前后对比。尿毒灵可以很好的改善糖尿病肾病肾功能不全患者临床症状,清除血中小分子毒素,增加患者血红蛋白的作用;未发现有明显的降血尿酸作用;未发现患者有任何不良反应,及不良事件的发生,毒副作用不明。
1.Objective and significance
The purpose of this study is the clinical effect of uremic Ling observed in strict accordance with the diagnostic criteria for inclusion criteria to select patients with drug use,and observe the points syndromes,biochemical indicators such as changes in;At the same time,the role of Hope for the uremic mechanisms to TGF/smad pathway targets for research,experimental study of exploratory;aimed at finding new treatments for DN on the experience of veteran experts who carried out the role of the clinical efficacy and mechanism at the same time,in order to prepare for the development of new drugs.
2.Method
Inpatient and outpatient diabetes were selected in line with the diagnostic criteria of DN patients,in line with the diagnostic criteria,serum creatinine 178≤(Cr)≤442ummol/l,to exclude other causes of renal dysfunction observed in patients with 30 cases observed for three months observed in patients with symptoms of drug use before and after integration, biochemical,blood lipids,liver function,blood changes,and the final effect.
SPF level 48 male Wister rats,weighing 180-220g,adaptive feeding week. Were randomly divided into normal control group 12,36 for the remainder of model.Selected as the model way to STZ(streptozotocin) + adenine ig:STZ used to buffer(2.1g of citric acid dissolved in 100ml double distilled water pair A liquid,2.44g sodium citrate dissolved in 100ml double distilled water for the B solution,A,B buffer solution is mixed) configuration,36 rats were fasted for 12 hours,STZ with a dose of 60mg/kg body weight,intraperitoneal injection of one-time,three days Random post-test blood glucose,blood glucose is greater than 16.1mmol/l of the rat,model successful,To reduce the mortality,rate of blood glucose greater than 25mmol/l in rat subcutaneous insulin ordinary 1-2iu,inadequate blood glucose 16.1mmol/l in rats, complement injection STZ 20mg/kg;all into a mold,the 2 percent to adenine, 300mg/kg administered every 7 days until the check into one orbital venous mode..Model the process five rats dead,after the mold into the remaining 31 rats,high to low according to serum creatinine levels,divided into model group,Niaoduling group、Niaoduqing group;model group,2-4ml orally given normal saline,NiaoduLing group to 0.432g/kg,Niaoduqing Niaoduqing group to 0.27g/kg;administration two months after the orbital venous plexus biochemical blood test,so take some kidney immunohistochemistry,kidneys do some RT-PCR.
3.Result
Experimental study components:treatment group compared with the model group,serum creatinine uremic spiritual group,blood urea nitrogen were statistically significant decline;Ling uremic group compared with the model group of cholesterol,triglyceride,low-density lipoprotein cholesterol were no significant differences,no statistical significance;TGF-β1,Smad3, Smad4,PhI-1 expression in model group than those in blank control group significantly increased,with statistical significance,P＜0.05,Ling uremic group than those in the above-mentioned protein expression in model group decreased significantly;RT-PCR detection of rat renal tissue TGF-β1mRNA, Smad3 mRNA,Smad4 mRNA,fluorescence quantitative PCR detection of various targets in the kidney tissue,the model group and blank group were significantly different,P＜0.05,Ling-uremic group Niaoduqing group compared with the model group significantly different,P＜0.05,statistically significant after administration.
Clinical Observation Part:
Effect of uremic Ling:5 cases markedly,accounting for 16.67%;21 cases effective,accounting for 70%;nulland void four cases,accounting for 13.33%; the total effective rate 86.67%.Control before and after medication,the patient symptom score was statistically significant decrease(P＜0.01).
Before and after contrast administration,patients with blood urea nitrogen,serum creatinine was statistically significant decrease(P＜0.05); patients with CHOL,TG and LDL-L reduction in the level of statistical significance(P＜0.05);the safety of drug use indicators of liver function no statistical significance before and after,blood leukocytes,no significant changes in red blood cells,hemoglobin increased.
4.Conclusion
Experimental studies by the following conclusion:a good soul uremic serum creatinine clearance,blood urea nitrogen,such as the role of toxins.Uremic Ling has a good reduction of transforming growth factor(TGF-β),plasminogen activator inhibitor(PAI-1) in the kidney of small ball,interstitial,tubular expression of TGF-β1 inhibition of mRNA synthesis.Therefore,it can be concluded that uremic TGF-β/Smad Ling can inhibit transduction pathway.Ling uremic TGF-β/Smad may be through inhibiting the transduction pathway,to achieve the inhibition of glomerular,renal interstitial fibrosis,tubular fibrosis,and thus play a role in renal protection.
Through clinical research,to observe the targets and safety indicators before and after contrast.A very good effect can be gained,renal failure symptoms in patients with uremic diabetic nephropathy was improved,removal of small and medium-sized molecules of blood toxins,to increase the role of hemoglobin;not found a clear role in lowering serum uric acid;not found any adverse reactions in patients,and adverse events the occurrence of unknown side effects.
本研究主要是对尿毒灵的临床疗效进行观察,对于严格按照诊断标准、纳入标准的情况下选取患者用药,并观察其证候积分、生化等指标变化;同时对于尿毒灵的作用机制,以TGF/smad转导通路为研究指标,进行探索性实验研究;至在寻找DN新的治疗药物,对名老专家经验方进行临床疗效及作用机制同时研究,为开发新药做好准备。
2.方法
住院和门诊的糖尿病人中筛选出符合DN诊断标准的病人,符合诊断标准,血肌酐178≤(Cr)≤442ummol/l,排除其它原因引起的肾功能不全,观察30例患者,观察三个月,观察用药前后患者症候积分、生化、血脂、肝功、血常规变化情况,及最后疗效。
SPF级雄性Wister大鼠48只,体重180-220g,适应性喂养一周。按体重随机分为正常对照组12只,剩余36只用于造模。造模方法选为STZ(链脲佐菌素)+腺嘌呤灌胃:将STZ用缓冲液(2.1g柠檬酸溶于100ml双蒸水中配成A液,2.44g柠檬酸钠溶于100ml双蒸水中为B液,A、B液混合即为缓冲液)配置,36只大鼠禁食12小时,STZ以剂量为60mg/kg体重,一次性腹腔注射,三天后测随机血糖,血糖大于16.1mmol/l的大鼠,造模成功,为减少死亡率血糖大于25mmol/l的大鼠皮下注射普通胰岛素1-2iu,血糖不足16.1mmol/l的大鼠,补注射STZ 20mg/kg;全部成模后,予2%腺嘌呤,300mg/kg灌胃,每7天取一次眶静脉血直至成模。造模过程中死亡5只,成模后剩余31只大鼠,按随机表随机分组,分为模型组、尿毒灵组、尿毒清组;模型组灌胃给予2-4ml生理盐水,尿毒灵组予尿毒灵组0.432g/kg,尿毒清组予尿毒清0.27g/kg;给药两个月后,眶静脉丛取血测生化指标,取部分肾脏做免疫组化,部分肾脏做RT-PCR。
3.结果
实验研究部分:给药组与模型组相比较,尿毒灵组血肌酐、尿素氮下降有统计学意义;尿毒灵组与模型组相比胆固醇、甘油三酯、低密度脂蛋白胆固醇差异不显著,无统计学意义;TGF-β1、Smad3、Smad4、PAI-1在模型组的表达均较空白组有明显增加,有统计学意义,P＜0.05,尿毒灵组上述蛋白的表达均较模型组有明显下降;RT-PCR检测大鼠肾组织TGF-β1mRNA、Smad3 mRNA、Smad4 mRNA,荧光定量PCR检测各指标在肾组织的表达,模型组与空白组比较有显著性差异,P＜0.05,尿毒灵组、尿毒清组与模型组相比差异显著,P＜0.05,给药后有统计学意义。
临床观察部分:
尿毒灵疗效:显效5例,占16.67%;有效21例,占70%;无效4例,占13.33%;总有效率86.67%。用药前后对照,患者症候积分下降有统计学意义(P＜0.01)。
用药前后对照,患者尿素氮,血肌酐下降有统计学意义(P＜0.05);患者CHOL、TG和LDL-L的水平下降有统计学意义(P＜0.05);安全性指标肝功能用药前后比较无统计学意义,血常规白细胞、红细胞无明显变化,血红蛋白有所上升。
4.结论
经实验研究得出如下结论:尿毒灵有很好的清除血中肌酐,尿素氮等毒素的作用。,尿毒灵具有很好的降低转化生长因子(TGF-β)、纤溶酶原激活物抑制物(PAI-1)在肾脏小球、间质、小管的表达,抑制TGF-β1、smad3、smad4 mRNA合成的作用。所以可以得出结论尿毒灵可以抑制TGF-β/Smad转导通路。尿毒灵可能是通过抑制TGF-β/Smad转导通路,而达到抑制肾小球、肾间质、肾小管纤维化,从而起到肾保护作用。
通过对尿毒灵的临床观察,对观察指标及安全性指标的前后对比。尿毒灵可以很好的改善糖尿病肾病肾功能不全患者临床症状,清除血中小分子毒素,增加患者血红蛋白的作用;未发现有明显的降血尿酸作用;未发现患者有任何不良反应,及不良事件的发生,毒副作用不明。
1.Objective and significance
The purpose of this study is the clinical effect of uremic Ling observed in strict accordance with the diagnostic criteria for inclusion criteria to select patients with drug use,and observe the points syndromes,biochemical indicators such as changes in;At the same time,the role of Hope for the uremic mechanisms to TGF/smad pathway targets for research,experimental study of exploratory;aimed at finding new treatments for DN on the experience of veteran experts who carried out the role of the clinical efficacy and mechanism at the same time,in order to prepare for the development of new drugs.
2.Method
Inpatient and outpatient diabetes were selected in line with the diagnostic criteria of DN patients,in line with the diagnostic criteria,serum creatinine 178≤(Cr)≤442ummol/l,to exclude other causes of renal dysfunction observed in patients with 30 cases observed for three months observed in patients with symptoms of drug use before and after integration, biochemical,blood lipids,liver function,blood changes,and the final effect.
SPF level 48 male Wister rats,weighing 180-220g,adaptive feeding week. Were randomly divided into normal control group 12,36 for the remainder of model.Selected as the model way to STZ(streptozotocin) + adenine ig:STZ used to buffer(2.1g of citric acid dissolved in 100ml double distilled water pair A liquid,2.44g sodium citrate dissolved in 100ml double distilled water for the B solution,A,B buffer solution is mixed) configuration,36 rats were fasted for 12 hours,STZ with a dose of 60mg/kg body weight,intraperitoneal injection of one-time,three days Random post-test blood glucose,blood glucose is greater than 16.1mmol/l of the rat,model successful,To reduce the mortality,rate of blood glucose greater than 25mmol/l in rat subcutaneous insulin ordinary 1-2iu,inadequate blood glucose 16.1mmol/l in rats, complement injection STZ 20mg/kg;all into a mold,the 2 percent to adenine, 300mg/kg administered every 7 days until the check into one orbital venous mode..Model the process five rats dead,after the mold into the remaining 31 rats,high to low according to serum creatinine levels,divided into model group,Niaoduling group、Niaoduqing group;model group,2-4ml orally given normal saline,NiaoduLing group to 0.432g/kg,Niaoduqing Niaoduqing group to 0.27g/kg;administration two months after the orbital venous plexus biochemical blood test,so take some kidney immunohistochemistry,kidneys do some RT-PCR.
3.Result
Experimental study components:treatment group compared with the model group,serum creatinine uremic spiritual group,blood urea nitrogen were statistically significant decline;Ling uremic group compared with the model group of cholesterol,triglyceride,low-density lipoprotein cholesterol were no significant differences,no statistical significance;TGF-β1,Smad3, Smad4,PhI-1 expression in model group than those in blank control group significantly increased,with statistical significance,P＜0.05,Ling uremic group than those in the above-mentioned protein expression in model group decreased significantly;RT-PCR detection of rat renal tissue TGF-β1mRNA, Smad3 mRNA,Smad4 mRNA,fluorescence quantitative PCR detection of various targets in the kidney tissue,the model group and blank group were significantly different,P＜0.05,Ling-uremic group Niaoduqing group compared with the model group significantly different,P＜0.05,statistically significant after administration.
Clinical Observation Part:
Effect of uremic Ling:5 cases markedly,accounting for 16.67%;21 cases effective,accounting for 70%;nulland void four cases,accounting for 13.33%; the total effective rate 86.67%.Control before and after medication,the patient symptom score was statistically significant decrease(P＜0.01).
Before and after contrast administration,patients with blood urea nitrogen,serum creatinine was statistically significant decrease(P＜0.05); patients with CHOL,TG and LDL-L reduction in the level of statistical significance(P＜0.05);the safety of drug use indicators of liver function no statistical significance before and after,blood leukocytes,no significant changes in red blood cells,hemoglobin increased.
4.Conclusion
Experimental studies by the following conclusion:a good soul uremic serum creatinine clearance,blood urea nitrogen,such as the role of toxins.Uremic Ling has a good reduction of transforming growth factor(TGF-β),plasminogen activator inhibitor(PAI-1) in the kidney of small ball,interstitial,tubular expression of TGF-β1 inhibition of mRNA synthesis.Therefore,it can be concluded that uremic TGF-β/Smad Ling can inhibit transduction pathway.Ling uremic TGF-β/Smad may be through inhibiting the transduction pathway,to achieve the inhibition of glomerular,renal interstitial fibrosis,tubular fibrosis,and thus play a role in renal protection.
Through clinical research,to observe the targets and safety indicators before and after contrast.A very good effect can be gained,renal failure symptoms in patients with uremic diabetic nephropathy was improved,removal of small and medium-sized molecules of blood toxins,to increase the role of hemoglobin;not found a clear role in lowering serum uric acid;not found any adverse reactions in patients,and adverse events the occurrence of unknown side effects.
引文
[1]王海燕.肾脏病学[S].北京:人民卫生出版社,2000,946.
[2]Liu S,Chen J,Sun J,et al.Existence of abnormal nitric oxide metabolism seen in glomerruli and inner medullary collecting duct in diabetic rats.Chin Med J(Engl),1997,110:515-519.
[3]孙岩,王秀玲,高锦凤,等.2型糖尿病肾病患者内皮素、血栓调节蛋白、血管内皮生长因子的变化及相关研究[J].中国血液净化.2006,5(6):316-319.
[4]郭明秋,李莉,苗翠,等.ACE基因和AT1R基因多态性与糖尿病相关性的研究[J].华中医学杂志.2007,31(1):25-27.
[5]徐浣白,张晓梅,孙卫华,等.AT1R 1166A/C基因多态性与糖尿病肾病的关系研究[J].山东医药.2007,47(28):10-12.
[6]华飞,刘为群,胡文来,等.ApoE基因多态性与2型糖尿病并发肾病的相关性研究[J].苏州大学学报:医学版.2006,26(5):837-838.
[7]杨斯韬,刘华,王玉明,等.P^22 phox基因C242T多态性与糖尿病肾病的相关性研究[J].昆明医学院学报.2006,27(4):111-115.
[8]张松,王睿,时立新.RANTES基因启动子多态性与2型糖尿病并发肾病的相关性[J].中国组织工程研究与临床康复.2007,11(17):3447-3450.
[9]金建,陈肖俊,郑景晨,等.G蛋白β3亚单位基因C825T等位基因多态性与糖尿病肾病的相关性[J].实用医学杂志.2006,22(24):2862-2864.
[10]FOGARTY DC,ZYCHMA M J。SCOTt L J。et ul.The C825Tpolymorphism in the human C-protein beta3 subunit gene is not associated with diabetic nephropathy in type Ⅰ diabetes mellitus[J].Diabetologia,1998,41(11):1304-1308.
[11]安新焕,宋滇平,刘华,等.IL-6基因启动子区-634C/G多态性与糖尿病肾病的相关性[J].中国糖尿病杂志.2007,15(5):289-291.
[12]朱锋,李红,吴芳,等.Decorin基因转染抑制高糖培养的大鼠肾系膜细胞细胞外基质mRNA表达[J].中国病理生理杂志.2007,23(9):1791-1795.
[13]陈文华.AR基因启动子区C-106T多态性与糖尿病肾病的相关性[J].齐鲁医学杂志.2007,22(2):131-133.
[14]冯传首,王云英,王培林,等.醛固酮合酶CYP11B2(-344C/T)基因多态性与2型糖尿病肾病的相关性[J].中国心血管杂志.2007,12(5):374-376.
[15]廖琳,林敏箐,陈淑薇,等.2型糖尿病患者内皮一氧化氮合酶基因(CA)n多态性的分布及与糖尿病肾病的关系[J].中华内分泌代谢杂志.2006,22(5):443-445.
[16]范贤明,李振华,候显明等.博莱霉素致大鼠肺纤维化过程中肺泡巨噬细胞STAT1的活化和蛋白表达的研究[J].中华结核和呼吸杂志,2002,25(1)57-58.
[17]赵松,史永红等,JAK/STAT信号途径参与高糖诱导的肾小管上皮细胞转分化.中国病理生理杂志,2008,24(2):325-329.
[18]中山医科大学第一医院肾内科.肾小球疾病中的间质损害.中华肾脏病杂志,2000;16(1):55-57.
[19]卢方平,郑法雷.胰岛素样生长因子与慢性肾衰竭患者的营养状况.中华肾脏病杂志,1998;14(1):62-63.
[20]Wolf G,Ziyodeh,FN,The role of angiotensin Ⅱ in diabetic nepgropathy:emphasis on nonhemodynamic mechanisms.Am J Kidney Dis,1997,29:153.
[21]Mogensen CF.Angiotension converting enzyme inhibitors and diabetic nephropathy,Br Med J,1992,304:327.
[22]李学旺.陈丽萌.调脂治疗对肾小球疾病的保护作用.中国实用内科杂志,2003,23(5):311.
[23]Hung CC,Tinn YG,Shyi Ts,et al,Insulin and heparin suppress superoxide production in diabetic rat glomeruli stimulated with lowdensity lipoprotein.Kidney,2001,59(suppl):124.
[24]Moriyama T,Oka K,Ueda H,et al.[J],Clin Exp Nephrol,2004,8(3):230-236.
[25]Shah S,Paparello J,Danesh FR,[J].Adv Chronic Kidney Dis,2005,12(2):187-195.
[26]Cruzado JM,Lloberas N,Torras J,et al.[J].Diabetes,2004,53(4):1119-1127.
[27]周英,蓝柳贵,封翠芸等.彭万年经方治疗糖尿病肾病经验举要.山东中医杂志.2006;25(11):773-774.
[28]冯健春,倪青.时振声教授治疗糖尿病肾病经验述要.辽宁中医杂志.2006,23(12):534-535
[29]贺学林,陈以平教授治疗糖尿病肾病临床经验.中西医结合肾病杂志,2000,1(1):7-8.
[30]李丽英,于宏,潘辑圣,等.黄芪与当归对肾病综合征患者总体蛋白质代谢的影响[J].中华内科杂志,1995,34(10):670.
[31]马俊,林善炎.大黄治疗慢性肾功能衰竭作用机制探讨[J].中国中西医结合杂志,1993,13(9):570-572.
[32]Liu ZH,Li YJ,Chen ZH et al.Glucose transporer in human glomerular mesangial cells modulated by transfrming growth factor-bata and rhein Acta Pharmacol Sin,2001,22(2):169.
[33]Zhang J,Liu ZH,Liu H et al.Reglatin of the expression and function of glucose transporter-1 by TGF-β1 and high glucose in mesangial cells.Chinese Medical Journal,2000,113:508.
[34]Zhang J,Liu ZH,Chen ZH et al.Effect of rheIn on glucose transporter-1expression and its function in glomerular mesangial cells.Chinese Medical Journal,1999,112;1077.
[35]李颖健,刘志虹,刘栋等.已糖胺通路的活化介导系膜细胞转化生长因子β1的表达.肾脏病与透析肾移植杂志,2000,9:303.
[36]刘志红,李颍健,朱加明等.葡萄糖转运蛋白对大鼠肾小球系膜细胞己糖胺通路的影响.中华内分泌代谢杂志,2001,17:370.
[37]刘志红,陈朝红,李颖健等.2型塘尿病肾病患者肾小球系膜细胞表塑及功能改变.中华医学杂志,2001,81:1369.
[38]李强,尿毒灵治疗慢性肾功能不全临床研究.2006级博士论文.
[39]郑筱萸,主编.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002,233-237。
[40]姚建,黎磊石.糖尿病肾病大鼠肾小球产生转化生长因子-β的研究[J].基础医学与临床,1994,14(3):40-43.
[41]Fuad NZ,Motohide I Sheldon C Inwolveent of the TGF-β system in the pathlgenesis of diabetic nephropathy[J]Clin Exp Nephrol 2002,(6):125-129.
[42]高燕凤,谢璇.转化生长因子-β1人类糖尿病肾病的临床意义[J].国外医学:内科学分册,2004,31(2):57-60.
[43]Derynck R,Zhang YE.Smad-dependent and Smad-independent path.ways in TGF-beta family signaling.Nature,2003,425(6958):577-584.
[44]Hirotaka F,Tatsuo Y,Hiroyuki S,et al Treatment with anti-TGF-β antibody acliorate chronic progressive nephritis by innibiting Smad/TGF-β signaling [J].Kidney Int.2004,65(1):63-74.
[45]赵玲,黄春林,卢富华.糖毒清对糖尿病肾病大鼠肾组织TGF-1mRNA及PAI-1表达的影响.广东医学,2006,27(2):188-189.
[46]Nosadina R,Tonalo G.Relationship between blood glucose control,pathogenesis and progression of diabetic nephropathy.J Am Soc Nephrol,2004,15(suppl):S1-5
[47]阎海,倪青.糖尿病并发症妙方[M].上海科学普及出版社,2002:43.
[48]赵玲,黄春林.糖毒清对糖尿病肾病肾功能不全大鼠生化指标的影响,中医药学刊.2006,24(6):1042-1044.
[49]史虹莉,方京冲,沈稚舟,等.弹性蛋白酶片对糖尿病肾病疗效观察[J].中华内分泌代谢杂志,1998,14(3):196
[50]苏励,陈湘君,胡建东等.不同剂量黄苠加丹参对大鼠蛋白尿作用比较[J].中国新药与临床杂志,2000,19(3):207.
[51]徐郁杰,张庆怡,陆敏,等.黄芪对糖尿病大鼠肾皮质TGF-β1表达的影响[J].中华内分泌代谢杂志,1998,14(5):312.
[52]洪小平,张欣洲,贺晓蕾,等.黄芪对糖尿病小鼠肾脏基因表达谱的影响.中国中药杂志,2008,33(6):676-680.
[53]陶少平,陈学峰,孙艳,等.黄芪注射液对糖尿病肾病病人血转化生长因子-β及Ⅳ型胶原水平的影响及其意义[J].中国中西医结合肾病杂志,2006,7(3):156-157.
[54]司廷林,侯慧珍.黄芪注射液对早期糖尿病肾病尿微量清蛋内及内皮素的影响[J].山东中医药大学学报,2007,31(1):36-37.
[55]祁忠华,林善琰.黄芪改善糖尿病早期肾血流动力学异常的研究.中国糖尿病杂志,1999,7(3):147-149.
[56]刘志红,黎磊石.探索糖尿病肾病防治的新途径[J].肾脏病与透析肾穆植杂志,2002,11(1):1-3.
[57]周华,王力宁,范秋灵,等.胰岛索及卡托普利对糖尿病大鼠肾小球蛋白激酶C活性的影响[J].中华肾脏杂志,2001,17(3):196.
[58]姚建,陈名道.糖尿病肾病及早期防治[J].中华内分泌代谢杂志,2002,14:331.
[59]Kondoh K,Hashiba M,Baba S.Inhibitory activity of clarithromycin on biofilm synthesis with pseudomonas aeruginosa Acta Otolaryngol,1996,525Suppl:56-60.
[60]National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification.Am J Kidney Dis,2002,39(2 suppl 1):S1-S266.
[61]Rigalleau V,Lasseur C,Perlemoine C,et al.Cockcroft-Gault form ula is biased by body weight in diabetic patients with renal paiment.Metabolism。2006,55:108-112.
[62]高玖鸣.ACEI和ARB联合治疗糖尿病肾病[J].药品评价,2008,5(8):355-358.
[63]Sniderman AD,Lamarche B,Tilley J,et al.Hypertriglyceridemic by perapoB in type 2 diabetes[J].Diabetes Care 2002,25(3):579-582
[64]Lamarche B,TchemofA,Morrjani s,et al.Small dense low-density lipoprotein particles as a predictor ofthe risk ofischemic heart disease in men:prospective results fromthe Quebec Cardiovascular Study[J].Circu—lation,1997,95:69-75.
[65]Cappuccio FP,Strazzullo P,Farinaro E,et al.Uric Acid Metabolism and Tubular Sodium Handling[J].JAMA,1993,270:354.
[66]张振文.痛风的危险因素[J].国外医学内分泌分册,1997,17(3):145.
[67]杨杉杉.老年糖尿病血尿酸与肾功能的关系[J].实用糖尿病杂志,2000,2(2):35.
[68]庄宏.高尿酸血症及老年人原发性痛风的研究[J].中华老年医学杂志,1993,12:314.
[69].Isono M,Chen S,Hong SW,et al.Smad pathway is activated in the diabetic mouse kindey and Smad3 mediated TGF-beta-induced fibronection in mesangial cells.Biochem Biophys Res Commun,2002.296:1356-1365.
[70]Chen R,Huang C,Morinelli TA,et al.Blockade of the effect of transforming growth factorβ1 on mesangial ceils by over expression of Smad7.J AM Soc Nephrol,2002,13(4):887-893.
[2]Liu S,Chen J,Sun J,et al.Existence of abnormal nitric oxide metabolism seen in glomerruli and inner medullary collecting duct in diabetic rats.Chin Med J(Engl),1997,110:515-519.
[3]孙岩,王秀玲,高锦凤,等.2型糖尿病肾病患者内皮素、血栓调节蛋白、血管内皮生长因子的变化及相关研究[J].中国血液净化.2006,5(6):316-319.
[4]郭明秋,李莉,苗翠,等.ACE基因和AT1R基因多态性与糖尿病相关性的研究[J].华中医学杂志.2007,31(1):25-27.
[5]徐浣白,张晓梅,孙卫华,等.AT1R 1166A/C基因多态性与糖尿病肾病的关系研究[J].山东医药.2007,47(28):10-12.
[6]华飞,刘为群,胡文来,等.ApoE基因多态性与2型糖尿病并发肾病的相关性研究[J].苏州大学学报:医学版.2006,26(5):837-838.
[7]杨斯韬,刘华,王玉明,等.P^22 phox基因C242T多态性与糖尿病肾病的相关性研究[J].昆明医学院学报.2006,27(4):111-115.
[8]张松,王睿,时立新.RANTES基因启动子多态性与2型糖尿病并发肾病的相关性[J].中国组织工程研究与临床康复.2007,11(17):3447-3450.
[9]金建,陈肖俊,郑景晨,等.G蛋白β3亚单位基因C825T等位基因多态性与糖尿病肾病的相关性[J].实用医学杂志.2006,22(24):2862-2864.
[10]FOGARTY DC,ZYCHMA M J。SCOTt L J。et ul.The C825Tpolymorphism in the human C-protein beta3 subunit gene is not associated with diabetic nephropathy in type Ⅰ diabetes mellitus[J].Diabetologia,1998,41(11):1304-1308.
[11]安新焕,宋滇平,刘华,等.IL-6基因启动子区-634C/G多态性与糖尿病肾病的相关性[J].中国糖尿病杂志.2007,15(5):289-291.
[12]朱锋,李红,吴芳,等.Decorin基因转染抑制高糖培养的大鼠肾系膜细胞细胞外基质mRNA表达[J].中国病理生理杂志.2007,23(9):1791-1795.
[13]陈文华.AR基因启动子区C-106T多态性与糖尿病肾病的相关性[J].齐鲁医学杂志.2007,22(2):131-133.
[14]冯传首,王云英,王培林,等.醛固酮合酶CYP11B2(-344C/T)基因多态性与2型糖尿病肾病的相关性[J].中国心血管杂志.2007,12(5):374-376.
[15]廖琳,林敏箐,陈淑薇,等.2型糖尿病患者内皮一氧化氮合酶基因(CA)n多态性的分布及与糖尿病肾病的关系[J].中华内分泌代谢杂志.2006,22(5):443-445.
[16]范贤明,李振华,候显明等.博莱霉素致大鼠肺纤维化过程中肺泡巨噬细胞STAT1的活化和蛋白表达的研究[J].中华结核和呼吸杂志,2002,25(1)57-58.
[17]赵松,史永红等,JAK/STAT信号途径参与高糖诱导的肾小管上皮细胞转分化.中国病理生理杂志,2008,24(2):325-329.
[18]中山医科大学第一医院肾内科.肾小球疾病中的间质损害.中华肾脏病杂志,2000;16(1):55-57.
[19]卢方平,郑法雷.胰岛素样生长因子与慢性肾衰竭患者的营养状况.中华肾脏病杂志,1998;14(1):62-63.
[20]Wolf G,Ziyodeh,FN,The role of angiotensin Ⅱ in diabetic nepgropathy:emphasis on nonhemodynamic mechanisms.Am J Kidney Dis,1997,29:153.
[21]Mogensen CF.Angiotension converting enzyme inhibitors and diabetic nephropathy,Br Med J,1992,304:327.
[22]李学旺.陈丽萌.调脂治疗对肾小球疾病的保护作用.中国实用内科杂志,2003,23(5):311.
[23]Hung CC,Tinn YG,Shyi Ts,et al,Insulin and heparin suppress superoxide production in diabetic rat glomeruli stimulated with lowdensity lipoprotein.Kidney,2001,59(suppl):124.
[24]Moriyama T,Oka K,Ueda H,et al.[J],Clin Exp Nephrol,2004,8(3):230-236.
[25]Shah S,Paparello J,Danesh FR,[J].Adv Chronic Kidney Dis,2005,12(2):187-195.
[26]Cruzado JM,Lloberas N,Torras J,et al.[J].Diabetes,2004,53(4):1119-1127.
[27]周英,蓝柳贵,封翠芸等.彭万年经方治疗糖尿病肾病经验举要.山东中医杂志.2006;25(11):773-774.
[28]冯健春,倪青.时振声教授治疗糖尿病肾病经验述要.辽宁中医杂志.2006,23(12):534-535
[29]贺学林,陈以平教授治疗糖尿病肾病临床经验.中西医结合肾病杂志,2000,1(1):7-8.
[30]李丽英,于宏,潘辑圣,等.黄芪与当归对肾病综合征患者总体蛋白质代谢的影响[J].中华内科杂志,1995,34(10):670.
[31]马俊,林善炎.大黄治疗慢性肾功能衰竭作用机制探讨[J].中国中西医结合杂志,1993,13(9):570-572.
[32]Liu ZH,Li YJ,Chen ZH et al.Glucose transporer in human glomerular mesangial cells modulated by transfrming growth factor-bata and rhein Acta Pharmacol Sin,2001,22(2):169.
[33]Zhang J,Liu ZH,Liu H et al.Reglatin of the expression and function of glucose transporter-1 by TGF-β1 and high glucose in mesangial cells.Chinese Medical Journal,2000,113:508.
[34]Zhang J,Liu ZH,Chen ZH et al.Effect of rheIn on glucose transporter-1expression and its function in glomerular mesangial cells.Chinese Medical Journal,1999,112;1077.
[35]李颖健,刘志虹,刘栋等.已糖胺通路的活化介导系膜细胞转化生长因子β1的表达.肾脏病与透析肾移植杂志,2000,9:303.
[36]刘志红,李颍健,朱加明等.葡萄糖转运蛋白对大鼠肾小球系膜细胞己糖胺通路的影响.中华内分泌代谢杂志,2001,17:370.
[37]刘志红,陈朝红,李颖健等.2型塘尿病肾病患者肾小球系膜细胞表塑及功能改变.中华医学杂志,2001,81:1369.
[38]李强,尿毒灵治疗慢性肾功能不全临床研究.2006级博士论文.
[39]郑筱萸,主编.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002,233-237。
[40]姚建,黎磊石.糖尿病肾病大鼠肾小球产生转化生长因子-β的研究[J].基础医学与临床,1994,14(3):40-43.
[41]Fuad NZ,Motohide I Sheldon C Inwolveent of the TGF-β system in the pathlgenesis of diabetic nephropathy[J]Clin Exp Nephrol 2002,(6):125-129.
[42]高燕凤,谢璇.转化生长因子-β1人类糖尿病肾病的临床意义[J].国外医学:内科学分册,2004,31(2):57-60.
[43]Derynck R,Zhang YE.Smad-dependent and Smad-independent path.ways in TGF-beta family signaling.Nature,2003,425(6958):577-584.
[44]Hirotaka F,Tatsuo Y,Hiroyuki S,et al Treatment with anti-TGF-β antibody acliorate chronic progressive nephritis by innibiting Smad/TGF-β signaling [J].Kidney Int.2004,65(1):63-74.
[45]赵玲,黄春林,卢富华.糖毒清对糖尿病肾病大鼠肾组织TGF-1mRNA及PAI-1表达的影响.广东医学,2006,27(2):188-189.
[46]Nosadina R,Tonalo G.Relationship between blood glucose control,pathogenesis and progression of diabetic nephropathy.J Am Soc Nephrol,2004,15(suppl):S1-5
[47]阎海,倪青.糖尿病并发症妙方[M].上海科学普及出版社,2002:43.
[48]赵玲,黄春林.糖毒清对糖尿病肾病肾功能不全大鼠生化指标的影响,中医药学刊.2006,24(6):1042-1044.
[49]史虹莉,方京冲,沈稚舟,等.弹性蛋白酶片对糖尿病肾病疗效观察[J].中华内分泌代谢杂志,1998,14(3):196
[50]苏励,陈湘君,胡建东等.不同剂量黄苠加丹参对大鼠蛋白尿作用比较[J].中国新药与临床杂志,2000,19(3):207.
[51]徐郁杰,张庆怡,陆敏,等.黄芪对糖尿病大鼠肾皮质TGF-β1表达的影响[J].中华内分泌代谢杂志,1998,14(5):312.
[52]洪小平,张欣洲,贺晓蕾,等.黄芪对糖尿病小鼠肾脏基因表达谱的影响.中国中药杂志,2008,33(6):676-680.
[53]陶少平,陈学峰,孙艳,等.黄芪注射液对糖尿病肾病病人血转化生长因子-β及Ⅳ型胶原水平的影响及其意义[J].中国中西医结合肾病杂志,2006,7(3):156-157.
[54]司廷林,侯慧珍.黄芪注射液对早期糖尿病肾病尿微量清蛋内及内皮素的影响[J].山东中医药大学学报,2007,31(1):36-37.
[55]祁忠华,林善琰.黄芪改善糖尿病早期肾血流动力学异常的研究.中国糖尿病杂志,1999,7(3):147-149.
[56]刘志红,黎磊石.探索糖尿病肾病防治的新途径[J].肾脏病与透析肾穆植杂志,2002,11(1):1-3.
[57]周华,王力宁,范秋灵,等.胰岛索及卡托普利对糖尿病大鼠肾小球蛋白激酶C活性的影响[J].中华肾脏杂志,2001,17(3):196.
[58]姚建,陈名道.糖尿病肾病及早期防治[J].中华内分泌代谢杂志,2002,14:331.
[59]Kondoh K,Hashiba M,Baba S.Inhibitory activity of clarithromycin on biofilm synthesis with pseudomonas aeruginosa Acta Otolaryngol,1996,525Suppl:56-60.
[60]National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification.Am J Kidney Dis,2002,39(2 suppl 1):S1-S266.
[61]Rigalleau V,Lasseur C,Perlemoine C,et al.Cockcroft-Gault form ula is biased by body weight in diabetic patients with renal paiment.Metabolism。2006,55:108-112.
[62]高玖鸣.ACEI和ARB联合治疗糖尿病肾病[J].药品评价,2008,5(8):355-358.
[63]Sniderman AD,Lamarche B,Tilley J,et al.Hypertriglyceridemic by perapoB in type 2 diabetes[J].Diabetes Care 2002,25(3):579-582
[64]Lamarche B,TchemofA,Morrjani s,et al.Small dense low-density lipoprotein particles as a predictor ofthe risk ofischemic heart disease in men:prospective results fromthe Quebec Cardiovascular Study[J].Circu—lation,1997,95:69-75.
[65]Cappuccio FP,Strazzullo P,Farinaro E,et al.Uric Acid Metabolism and Tubular Sodium Handling[J].JAMA,1993,270:354.
[66]张振文.痛风的危险因素[J].国外医学内分泌分册,1997,17(3):145.
[67]杨杉杉.老年糖尿病血尿酸与肾功能的关系[J].实用糖尿病杂志,2000,2(2):35.
[68]庄宏.高尿酸血症及老年人原发性痛风的研究[J].中华老年医学杂志,1993,12:314.
[69].Isono M,Chen S,Hong SW,et al.Smad pathway is activated in the diabetic mouse kindey and Smad3 mediated TGF-beta-induced fibronection in mesangial cells.Biochem Biophys Res Commun,2002.296:1356-1365.
[70]Chen R,Huang C,Morinelli TA,et al.Blockade of the effect of transforming growth factorβ1 on mesangial ceils by over expression of Smad7.J AM Soc Nephrol,2002,13(4):887-893.